Catalyst Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Catalyst Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-135	Closed	-$25K	–	427
2021 Q2	$25K	Buy	135 +5	+4%	+$858	﹤0.01%	351
2021 Q1	$20K	Sell	130 -24	-16%	-$3.71K	﹤0.01%	325
2020 Q4	$24K	Buy	+154	New	+$19.8K	﹤0.01%	308
2018 Q1	–	Sell	-13,000	Closed	-$1.55M	–	584
2017 Q4	$1.55M	Buy	13,000 +8,050	+163%	+$980K	0.06%	146
2017 Q3	$694K	Buy	+4,950	New	+$673K	0.03%	191
2016 Q2	–	Sell	-5,000	Closed	-$696K	–	580
2016 Q1	$696K	Sell	5,000 -5,175	-51%	-$760K	0.12%	137
2015 Q4	$1.94M	Hold	10,175	–	–	0.28%	91
2015 Q3	$1.59M	Sell	10,175 -20,000	-66%	-$3.65M	0.21%	109
2015 Q2	$5.46M	Buy	30,175 +30,000	+17,143%	+$5.18M	0.64%	66
2015 Q1	$30K	Hold	175	–	–	﹤0.01%	363
2014 Q4	$32K	Hold	175	–	–	﹤0.01%	363
2014 Q3	$29K	Buy	+175	New	+$28.7K	﹤0.01%	334

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Catalyst Capital Advisors's ALXN Position: Q3 2021 in Review

Catalyst Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 135 shares — an estimated $25K sold.

Catalyst Capital Advisors first reported a position in ALXN in Q3 2014 and held it in 12 quarters. The position peaked at $5.46M in Q2 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Catalyst Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Catalyst Capital Advisors sold 135 Alexion Pharmaceuticals shares in Q3 2021, an estimated $25K.
Catalyst Capital Advisors first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 12 quarters.
Catalyst Capital Advisors's Alexion Pharmaceuticals position peaked at $5.46M in Q2 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Catalyst Capital Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.